JP2018505146A5 - - Google Patents

Download PDF

Info

Publication number
JP2018505146A5
JP2018505146A5 JP2017533789A JP2017533789A JP2018505146A5 JP 2018505146 A5 JP2018505146 A5 JP 2018505146A5 JP 2017533789 A JP2017533789 A JP 2017533789A JP 2017533789 A JP2017533789 A JP 2017533789A JP 2018505146 A5 JP2018505146 A5 JP 2018505146A5
Authority
JP
Japan
Prior art keywords
amino
ethoxy
chem
acetyl
carboxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017533789A
Other languages
English (en)
Japanese (ja)
Other versions
JP6727210B2 (ja
JP2018505146A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/080969 external-priority patent/WO2016102562A1/en
Publication of JP2018505146A publication Critical patent/JP2018505146A/ja
Publication of JP2018505146A5 publication Critical patent/JP2018505146A5/ja
Application granted granted Critical
Publication of JP6727210B2 publication Critical patent/JP6727210B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017533789A 2014-12-23 2015-12-22 Fgf21誘導体及びその使用 Active JP6727210B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199935.9 2014-12-23
EP14199935 2014-12-23
PCT/EP2015/080969 WO2016102562A1 (en) 2014-12-23 2015-12-22 Fgf21 derivatives and uses thereof

Publications (3)

Publication Number Publication Date
JP2018505146A JP2018505146A (ja) 2018-02-22
JP2018505146A5 true JP2018505146A5 (enExample) 2018-11-29
JP6727210B2 JP6727210B2 (ja) 2020-07-22

Family

ID=52130150

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017533789A Active JP6727210B2 (ja) 2014-12-23 2015-12-22 Fgf21誘導体及びその使用

Country Status (24)

Country Link
US (3) US9744213B2 (enExample)
EP (1) EP3236991B1 (enExample)
JP (1) JP6727210B2 (enExample)
KR (1) KR102427527B1 (enExample)
CN (1) CN107108709B (enExample)
AR (1) AR103246A1 (enExample)
AU (1) AU2015371056B2 (enExample)
DK (1) DK3236991T3 (enExample)
ES (1) ES2742503T3 (enExample)
HK (1) HK1246156B (enExample)
HR (1) HRP20191292T1 (enExample)
HU (1) HUE044783T2 (enExample)
IL (1) IL252438B (enExample)
MX (1) MX377044B (enExample)
MY (1) MY181181A (enExample)
PL (1) PL3236991T3 (enExample)
PT (1) PT3236991T (enExample)
RS (1) RS59154B1 (enExample)
RU (1) RU2729011C2 (enExample)
SA (1) SA517381673B1 (enExample)
SI (1) SI3236991T1 (enExample)
TW (2) TWI708781B (enExample)
WO (1) WO2016102562A1 (enExample)
ZA (1) ZA201703768B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102433503B1 (ko) 2016-05-24 2022-08-18 노보 노르디스크 에이/에스 Mic-1 화합물 및 이것의 사용
CN106421753A (zh) * 2016-10-19 2017-02-22 哈尔滨医科大学 重组人成纤维细胞生长因子‑21在制备预防和治疗缺血性心律失常药物中的应用
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Mic-1化合物及其用途
WO2019043457A2 (en) 2017-09-04 2019-03-07 89Bio Ltd. CONJUGATES OF MUTANT PEPTIDE FGF-21 AND USES THEREOF
KR20210027426A (ko) 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 Fgf21 제제
US11427623B1 (en) 2019-05-28 2022-08-30 89Bio Ltd. Methods of treatment using mutant FGF-21 peptide conjugates
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
EP4089108A1 (en) 2021-05-11 2022-11-16 CytoKi Pharma ApS Therapeutic derivatives of interleukin-22
US20240279297A1 (en) 2021-05-11 2024-08-22 Cytoki Pharma Aps Therapeutic derivatives of interleukin-22
KR102631925B1 (ko) * 2021-06-10 2024-02-01 토드제약 주식회사 신규 fgf21 변이체 개발 및 이의 생산기법과 용도
WO2023284822A1 (en) * 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders
JP2024531980A (ja) * 2021-09-08 2024-09-03 リートー ラボラトリーズ カンパニー リミテッド Fgf21変異タンパク質及びその応用
MA71385A (fr) 2022-07-08 2025-04-30 Novo Nordisk A/S Composés isvd hautement puissants capables de remplacer fviii(a)
US12098400B2 (en) 2022-07-08 2024-09-24 Novo Nordisk A/S Highly potent ISVD compounds capable of substituting for FVIII(A)
AR132255A1 (es) 2023-03-30 2025-06-11 Novo Nordisk As Compuestos de fusión y usos de estos
CN121194798A (zh) * 2023-05-12 2025-12-23 诺和诺德股份有限公司 长效生长激素受体拮抗剂及其用途
KR20250039299A (ko) 2023-09-11 2025-03-20 노보 노르디스크 에이/에스 항-il-6 도메인 항체
CN118307684B (zh) * 2024-06-11 2024-10-18 北京志道生物科技有限公司 一种经脂肪酸链修饰的glp-1-fgf21融合蛋白及其制备方法和应用
WO2026012311A1 (zh) * 2024-07-08 2026-01-15 浙江道尔生物科技有限公司 Fgf21衍生物及其用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
EP1329227A1 (en) 2002-01-22 2003-07-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells
ES2371072T3 (es) 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
EP1670515A2 (en) 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
TW200522976A (en) 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
EP2270163A1 (en) 2003-12-10 2011-01-05 Eli Lilly and Company Muteins of fibroblast growth factor 21
CN101665538A (zh) 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
WO2005091944A2 (en) 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
PL1751184T3 (pl) 2004-05-13 2010-02-26 Lilly Co Eli Białka fuzyjne FGF-21
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
ES2542228T3 (es) 2004-07-08 2015-08-03 Novo Nordisk A/S Marcas de prolongación polipeptídica que comprenden un resto de tetrazol
EP1789443A1 (en) 2004-09-02 2007-05-30 Eli Lilly And Company Muteins of fibroblast growth factor 21
BRPI0514790A (pt) 2004-09-02 2008-06-24 Lilly Co Eli muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
JP2008522617A (ja) 2004-12-14 2008-07-03 イーライ リリー アンド カンパニー 線維芽細胞成長因子21の突然変異タンパク質
EP1846019A2 (en) 2005-01-21 2007-10-24 Eli Lilly And Company Method for treating cardiovascular disease
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US20100022446A1 (en) 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
SI2068909T1 (sl) 2007-03-30 2012-09-28 Ambrx Inc Modificirani fgf-21 polipeptidi in njihova uporaba
US20110034373A1 (en) 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CN100587073C (zh) 2008-03-24 2010-02-03 吉林农大生物反应器工程有限公司 人成纤维细胞生长因子-21的重组表达
SG193860A1 (en) * 2008-06-04 2013-10-30 Amgen Inc Fgf21 mutants and uses thereof
NZ592009A (en) * 2008-10-10 2012-11-30 Amgen Inc Fgf21 mutants and uses thereof
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
CN102361647B (zh) * 2009-01-23 2018-02-16 诺沃-诺迪斯克有限公司 具有白蛋白结合剂a‑b‑c‑d‑e‑的fgf21衍生物及其应用
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
BRPI1011404B1 (pt) 2009-05-05 2022-05-03 Amgen Inc Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
US20120035099A1 (en) 2009-06-11 2012-02-09 Novo Nordisk A/S Fgf21 analogues and derivatives
CN102802657A (zh) 2009-06-11 2012-11-28 诺沃-诺迪斯克有限公司 用于治疗2型糖尿病的glp-1和fgf21组合
JP2013533227A (ja) * 2010-06-08 2013-08-22 ノヴォ ノルディスク アー/エス Fgf21類似体および誘導体
CN103415300B (zh) * 2010-07-20 2018-02-23 诺沃—诺迪斯克有限公司 N‑末端修饰的fgf21化合物
WO2013033452A2 (en) * 2011-08-31 2013-03-07 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
MX2015002985A (es) * 2012-09-07 2015-06-22 Sanofi Sa Proteinas de fusion para el tratamiento de un sindrome metabolico.
MX383664B (es) * 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.

Similar Documents

Publication Publication Date Title
RU2017125050A (ru) Производные fgf21 и их применения
JP2013532644A5 (enExample)
JP2013533227A5 (enExample)
JP2012529463A5 (enExample)
MY161450A (en) Double-acylated glp-1 derivatives
HRP20201881T1 (hr) Spojevi koji su suagonisti glukagona i glp-1
JP2013543497A5 (enExample)
JP2017528419A5 (enExample)
PH12019500074A1 (en) Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease
FI3727426T3 (fi) Inkretiinianalogeja ja niiden käyttötarkoituksia
JP2017500289A5 (enExample)
JP2017502024A5 (enExample)
JP2016500682A5 (enExample)
JP2012506402A5 (enExample)
CY1113299T1 (el) Πολυπεπτιδια απροτινινης για τη μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο
JP2016526012A5 (enExample)
JP2014224121A5 (enExample)
JP2016153410A5 (enExample)
JP2017081939A5 (enExample)
RU2015146614A (ru) Конъюгированная вакцина на основе пептида антигена wt1
ATE527353T1 (de) Pdgf-bindendes polypeptid aus protein a
JP2013518115A5 (enExample)
WO2012069836A3 (en) Biologically active complex and its preparation
EP3963063A4 (en) COMPOSITIONS FOR THE TREATMENT OF POMPE'S DISEASE
JP2016523241A5 (enExample)